U.S. Acute Myeloid Leukemia Diagnostics Market to 2032
Overview
The U.S. Acute Myeloid Leukemia Diagnostics Market is expected to reach a 2,225.09 USD Million by 2032 and is projected to grow at a CAGR of 17.70% from 2025 to 2032.
Revenue, 2024 (USD Million)
893.57
Forecast, 2032 (USD Million)
2,225.09
CAGR, 2024 - 2032
17.70%
Report Coverage
U.S.
U.S. Acute Myeloid Leukemia Diagnostics Market 2018-2032 USD Million
U.S. Acute Myeloid Leukemia Diagnostics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 893.57 USD Million
- Projected Market Size (2032): 2,225.09 USD Million
- CAGR (2025-2032): 17.70%
Key Findings of U.S. Acute Myeloid Leukemia Diagnostics Market
- The U.S. Acute Myeloid Leukemia Diagnostics Market was valued at 893.57 USD Million in 2024.
- The U.S. Acute Myeloid Leukemia Diagnostics Market is likely to grow at a CAGR of 17.70% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment 65 and Above in Age Group Segment accounted for the largest share of the market with a revenue of 691.02 USD Million
- The fastest growing segment Myeloblastic (M0) in Cancer Segment grew Fastest with a CAGR of 24.81% during the forecast period from 2024 to 2032.
U.S. Acute Myeloid Leukemia Diagnostics Market Scope
U.S. Acute Myeloid Leukemia Diagnostics Market Segmentation & Scope
Product
- Consumables & Accessories
- Instruments
Test
- Others
- Immunophenotyping
- Biomarker Test
- Genetic Tests
- Bone Marrow Tests
- Imaging Test
- Blood Test
End User
- Others
- Cancer Research Institutes
- Diagnostic Imaging Centers
- Independent Diagnostic Laboratories
- Associated Labs
- Hospitals
Distribution Channel
- Retail Sales
- Direct Tender
Cancer
- Megakaryocytic (M7)
- Erythroleukemia (M6)
- Monocytic (M5)
- Myelomonocytic (M4)
- Promyelocytic (M3)
- Myeloblastic (M2)
- Myeloblastic (M1)
- Myeloblastic (M0)
Age Group
- 21-29
- Below 21
- 30-65
- 65 and Above
Gender
- Female
- Male
U.S. Acute Myeloid Leukemia Diagnostics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2021 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 893.57 USD Million |
| Market Value in 2032 | 2,225.09 USD Million |
| CAGR (2025-2032) | 17.70% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Product,Test,End User,Distribution Channel,Cancer,Age Group,Gender |
Regional Insights:
-
Leading Market (2024-2032): U.S., leading in terms of revenue 893.57 USD Million in 2024
- Key Country: U.S., leading in terms of revenue with value of 893.57 USD Million in 2024.
Segments and Scope
-
U.S. Acute Myeloid Leukemia Diagnostics Market to 2032, By Product
- Instruments is the largest segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 626.34 USD Million in the year 2024.
- Instruments is the Fastest growing segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 18.60 % in forecast period 2025-2032.
-
U.S. Acute Myeloid Leukemia Diagnostics Market to 2032, By Test
- Blood Test is the largest segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 285.85 USD Million in the year 2024.
- Blood Test is the Fastest growing segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 22.05 % in forecast period 2025-2032.
-
U.S. Acute Myeloid Leukemia Diagnostics Market to 2032, By End User
- Hospitals is the largest segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 314.60 USD Million in the year 2024.
- Hospitals is the Fastest growing segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 22.10 % in forecast period 2025-2032.
-
U.S. Acute Myeloid Leukemia Diagnostics Market to 2032, By Distribution Channel
- Direct Tender is the largest segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 611.25 USD Million in the year 2024.
- Direct Tender is the Fastest growing segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 19.54 % in forecast period 2025-2032.
-
U.S. Acute Myeloid Leukemia Diagnostics Market to 2032, By Cancer
- Myeloblastic (M0) is the largest segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 253.48 USD Million in the year 2024.
- Myeloblastic (M0) is the Fastest growing segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 24.81 % in forecast period 2025-2032.
-
U.S. Acute Myeloid Leukemia Diagnostics Market to 2032, By Age Group
- 65 and Above is the largest segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 691.02 USD Million in the year 2024.
- 65 and Above is the Fastest growing segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 18.49 % in forecast period 2025-2032.
-
U.S. Acute Myeloid Leukemia Diagnostics Market to 2032, By Gender
- Male is the largest segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a revenue of 520.52 USD Million in the year 2024.
- Male is the Fastest growing segment in U.S. Acute Myeloid Leukemia Diagnostics Market to 2032 with a Growth rate of 19.66 % in forecast period 2025-2032.
U.S. Acute Myeloid Leukemia Diagnostics Market Company Share Analysis
| Company Name |
|
||
| Myriad Genetics, Inc. | |||
| Sysmex Corporation | |||
| QIAGEN | |||
| BIOMÉRIEUX | |||
| CANON MEDICAL SYSTEMS CORPORATION | |||
U.S. Acute Myeloid Leukemia Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Million
U.S. Acute Myeloid Leukemia Diagnostics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The U.S. Acute Myeloid Leukemia Diagnostics Market is segmented based on Segmentation Product,Test,End User,Distribution Channel,Cancer,Age Group,Gender.
U.S. Acute Myeloid Leukemia Diagnostics Market was valued at USD 893.57(Revenue in USD Million) in 2021.
U.S. Acute Myeloid Leukemia Diagnostics Market is projected to grow at a CAGR of 17.70% during the forecast period of 2024 to 2032.
The 65 and Above segment is expected to dominate the U.S. Acute Myeloid Leukemia Diagnostics Market, holding a largest market share of 691.02 USD Million in 2024
U.S. Acute Myeloid Leukemia Diagnostics Market Scope
U.S. Acute Myeloid Leukemia Diagnostics Market Segmentation & Scope
Product
- Consumables & Accessories
- Instruments
Test
- Others
- Immunophenotyping
- Biomarker Test
- Genetic Tests
- Bone Marrow Tests
- Imaging Test
- Blood Test
End User
- Others
- Cancer Research Institutes
- Diagnostic Imaging Centers
- Independent Diagnostic Laboratories
- Associated Labs
- Hospitals
Distribution Channel
- Retail Sales
- Direct Tender
Cancer
- Megakaryocytic (M7)
- Erythroleukemia (M6)
- Monocytic (M5)
- Myelomonocytic (M4)
- Promyelocytic (M3)
- Myeloblastic (M2)
- Myeloblastic (M1)
- Myeloblastic (M0)
Age Group
- 21-29
- Below 21
- 30-65
- 65 and Above
Gender
- Female
- Male
Frequently Asked Questions
The U.S. Acute Myeloid Leukemia Diagnostics Market is segmented based on Segmentation Product,Test,End User,Distribution Channel,Cancer,Age Group,Gender.
U.S. Acute Myeloid Leukemia Diagnostics Market was valued at USD 893.57(Revenue in USD Million) in 2021.
U.S. Acute Myeloid Leukemia Diagnostics Market is projected to grow at a CAGR of 17.70% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Acute Myeloid Leukemia Diagnostics Market for final year is USD 2,225.09 (USD Million).
U.S. Acute Myeloid Leukemia Diagnostics Market Company Profiling
Frequently Asked Questions
The U.S. Acute Myeloid Leukemia Diagnostics Market is segmented based on Segmentation Product,Test,End User,Distribution Channel,Cancer,Age Group,Gender.
U.S. Acute Myeloid Leukemia Diagnostics Market was valued at USD 893.57(Revenue in USD Million) in 2021.
U.S. Acute Myeloid Leukemia Diagnostics Market is projected to grow at a CAGR of 17.70% during the forecast period of 2024 to 2032.
The estimated market value of the U.S. Acute Myeloid Leukemia Diagnostics Market for final year is USD 2,225.09 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.